The new coronary vaccine that requires only one dose is the Recombinant Novel Coronary Virus Vaccine (Adenovirus Vector Type 5). Recombinant New Coronavirus Vaccine (Adenovirus Vector Type 5), a recombinant new coronavirus vaccine with human replication-defective adenovirus as the carrier, requires only 1 dose to complete the basic immunization, and is applicable to persons aged 18 years and above. Persons who have completed 1 dose of Adenovirus Vector Vaccine as basic immunization and have been vaccinated for 6 months and above may also receive 1 dose of Adenovirus Vector Vaccine as booster immunization. The principle of adenovirus vector vaccine is to use an artificially modified harmless adenovirus as a vector, in which the protein gene of a new coronavirus is loaded, and then injected into the body to stimulate the production of antibodies. A small number of people may experience side effects such as pain at the injection site, headache, fatigue, muscle pain and nausea after injection. Most of these side effects are mild and usually last for 1 to 2 days and can be relieved on their own. For recombinant novel coronavirus vaccine (adenovirus vector type 5), it is necessary to go to the vaccination site and rule out contraindications for vaccination before vaccination. Consult your doctor for details before use.